short term use of glp 1 GLP-1 receptor agonists GLP-1 Medications Clinic Near Me

The STEP 1 trial of once-weekly injectable semaglutide reported substantial average weight loss in adults with obesity, as published in the New England Journal of Medicine

This is a mechanism no approved drug currently uses Phase 2 trials showed up to 24% body weight reduction over 48 weeks, meaningfully exceeding tirzepatide and semaglutide outcomes Phase 3 trials are currently underway

Hormonal decline in men is a gradual process that often goes unrecognized for years

However, clinical data specifically evaluating their concurrent use are lacking, so theoretical considerations and individual patient factors must guide decision-making with healthcare provider input